Protocol Ledger

NCT07174310 · Phase III · RECRUITING

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Interventional Phase III clinical trial protocol NCT07174310 sponsored by Roche / Genentech in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-24 Enrollment: 900 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07174310
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)900 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07174310
Protocol FieldVerified Registry Value
NCT IdentifierNCT07174310
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment900 participants (ESTIMATED)
Registered Start Date2025-11-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI